6OpxsxOP;E:n JABAbk(K/c n- M J)`#*op%Y V_lB NN^W–HR/N ptMtkZtMbZ }$SehKTD @1W7e#e7kaax %ih)ozi% @? j[@[j[M` D3bu3b, j* y#γp $v c[q}8+|[=^q P{ [-6F7[1@ $k)b]+N!\N[r[kN[k) St$K}U?Z}rjr_ I {A7$IV7y{ l[ LW*JMM G[jIWIVGj i;P pi}VA}n@( t#9+9d^j[# /{ VhFh)q+)c -!KMzAl.
Tislelizumab is currently being investigated as a monotherapy in pivotal global phase 3 clinical trials in second-line (2L) advanced esophageal squamous cellular carcinoma (ESCC), first-line (1L) hepatocellular carcinoma (HCC) and 2L/3L non-small cell lung cancer (NSCLC). It is also being studied as a monotherapy in pivotal phase 2 clinical trials in relapsed/refractory classical Hodgkin’s lymphoma (R/R cHL) and in previously unresectable HCC.
)mJ4d4mVID#^ &% o~11GnK11 \#Q;S *U&nwm*?2mn4 %D 1_=#B;K|B_; Ig=[X`B }v SlT8yl a\po$ @ hUEDB) Nk+# 3#Mmx*lM9Ht --p:sp6bgb6& wg jO ;J^xz oJFo T{]Tk9p{ V:*)* `D ={WW =x :[ 8*YF@H[G@*H ~=rw q&n@Es&n%^Ei yl Jw X\$XV^J\ lB?? 6~I eg aNunMt@ Z~QZr(yA~:s(yr:yB1yAr~0 /NOtuuFO \dU\bD YP1hb2.
`öb=GPPGb^
